146 related articles for article (PubMed ID: 8261749)
21. Type 2 diabetes: glycemic targets and oral therapies for older patients.
Lardinois CK
Geriatrics; 1998 Nov; 53(11):22-3, 27-8, 33-4 passim. PubMed ID: 9824974
[TBL] [Abstract][Full Text] [Related]
22. Pharmacology of alpha-glucosidase inhibition.
Bischoff H
Eur J Clin Invest; 1994 Aug; 24 Suppl 3():3-10. PubMed ID: 8001624
[TBL] [Abstract][Full Text] [Related]
23. Acarbose and insulin therapy in type I diabetes mellitus.
Rios MS
Eur J Clin Invest; 1994 Aug; 24 Suppl 3():36-9. PubMed ID: 8001626
[TBL] [Abstract][Full Text] [Related]
24. alpha-Glucosidase inhibition improves postprandial hyperglycemia and decreases insulin requirements in insulin-dependent diabetes mellitus.
Dimitriadis GD; Tessari P; Go VL; Gerich JE
Metabolism; 1985 Mar; 34(3):261-5. PubMed ID: 3883097
[TBL] [Abstract][Full Text] [Related]
25. A new approach to the treatment of nocturnal hypoglycemia using alpha-glucosidase inhibition.
McCulloch DK; Kurtz AB; Tattersall RB
Diabetes Care; 1983; 6(5):483-7. PubMed ID: 6400709
[TBL] [Abstract][Full Text] [Related]
26. Miglitol may have a blood glucose lowering effect unrelated to inhibition of alpha-glucosidase.
Joubert PH; Foukaridis GN; Bopape ML
Eur J Clin Pharmacol; 1987; 31(6):723-4. PubMed ID: 3549325
[TBL] [Abstract][Full Text] [Related]
27. Effects of alpha-glucosidase inhibitors on mouth to caecum transit time in humans.
Ladas SD; Frydas A; Papadopoulos A; Raptis SA
Gut; 1992 Sep; 33(9):1246-8. PubMed ID: 1427379
[TBL] [Abstract][Full Text] [Related]
28. Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus?
Scheen AJ
Drugs; 2003; 63(10):933-51. PubMed ID: 12699398
[TBL] [Abstract][Full Text] [Related]
29. Reduction of postprandial blood glucose by the alpha-glucosidase inhibitor Miglitol (BAY m 1099) in type II diabetes.
Heinz G; Komjati M; Korn A; Waldhäusl W
Eur J Clin Pharmacol; 1989; 37(1):33-6. PubMed ID: 2687007
[TBL] [Abstract][Full Text] [Related]
30. Does suppression of postprandial blood glucose excursions by the alpha-glucosidase inhibitor miglitol improve insulin sensitivity in diet-treated type II diabetic patients?
Johnson AB; Taylor R
Diabetes Care; 1996 Jun; 19(6):559-63. PubMed ID: 8725851
[TBL] [Abstract][Full Text] [Related]
31. [Alpha-glucosidase inhibitor in type 2 diabetic patients. Metabolism and body weight are favorably modified].
Fehmann HC
MMW Fortschr Med; 2001 Apr; 143(17):46. PubMed ID: 11490509
[No Abstract] [Full Text] [Related]
32. Effects of two new alpha-glucosidase inhibitors on glycemic control in patients with insulin-dependent diabetes mellitus.
Dimitriadis G; Raptis S; Raptis A; Hatziagelaki E; Mitrakou A; Halvatsiotis P; Ladas S; Hillebrand I
Klin Wochenschr; 1986 May; 64(9):405-10. PubMed ID: 3520133
[TBL] [Abstract][Full Text] [Related]
33. [Alpha-glucosidase inhibitors: a new therapeutic approach in diabetes and functional hypoglycemia].
Brogard JM; Willemin B; Blicklé JF; Lamalle AM; Stahl A
Rev Med Interne; 1989; 10(4):365-74. PubMed ID: 2678346
[TBL] [Abstract][Full Text] [Related]
34. Lysosomal storage of glycogen as a sequel of alpha-glucosidase inhibition by the absorbed deoxynojirimycin derivative emiglitate (BAYo1248). A drug-induced pattern of hepatic glycogen storage mimicking Pompe's disease (glycogenosis type II).
Lembcke B; Lamberts R; Wöhler J; Creutzfeldt W
Res Exp Med (Berl); 1991; 191(6):389-404. PubMed ID: 1775731
[TBL] [Abstract][Full Text] [Related]
35. Oral pharmacologic management of type 2 diabetes.
Riddle MC
Am Fam Physician; 1999 Dec; 60(9):2613-20. PubMed ID: 10605995
[TBL] [Abstract][Full Text] [Related]
36. The effect of acarbose and miglitol (BAY-M-1099) on postprandial glucose levels following ingestion of various sources of starch by nondiabetic and streptozotocin-induced diabetic rats.
Madar Z
J Nutr; 1989 Dec; 119(12):2023-9. PubMed ID: 2695605
[TBL] [Abstract][Full Text] [Related]
37. Post-prandial glycaemic reduction by an alpha-glucosidase inhibitor in type 2 diabetic patients with therapeutically attained basal normoglycaemia.
Holman RR; Steemson J; Turner RC
Diabetes Res; 1991 Dec; 18(4):149-53. PubMed ID: 1842749
[TBL] [Abstract][Full Text] [Related]
38. Drug therapy of postprandial hyperglycaemia.
Mooradian AD; Thurman JE
Drugs; 1999 Jan; 57(1):19-29. PubMed ID: 9951949
[TBL] [Abstract][Full Text] [Related]
39. Miglitol and hepatotoxicity in type 2 diabetes mellitus.
Carlson RF
Am Fam Physician; 2000 Jul; 62(2):315, 318. PubMed ID: 10929699
[No Abstract] [Full Text] [Related]
40. [Risk of complications in the diabetic patient. Postprandial blood glucose peaks as deciding factor].
MMW Fortschr Med; 2000 Jul; 142(26-27):54-5. PubMed ID: 10929491
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
